ipratropium bromide / Generic mfg. - LARVOL DELTA

Repeated bronchoscopies in an asthma trial: multi-disciplinary (nursing, physician, scientist) experience of four procedures per subject over 6 weeks (ERS 2026) - P4 | "MAELABA RBs were performed at 2-week intervals: at baseline, and after 2 weeks each of salmeterol monotherapy, a washout period, and salmeterol-fluticasone combination therapy, to assess β2-agonist effects on gene expression...All were pre-treated with nebulised ipratropium bromide and recovered safe for discharge within 2 hours...One RB-related adverse event was recorded (chest pain without pathology) requiring emergency assessment but not hospital admission. Conclusions Repeated lower airway sampling during an asthma clinical trial was safe, well tolerated, and provided reliable, high quality airway samples."

Clinical • Asthma • Immunology • Respiratory Diseases

Efficacy of Personalized Multi-Ingredient Nasal Sprays in Patients With Rhinitis (AAO-HNSF 2026) - "Formulations included FDA-approved medications— triamcinolone 0.055%-0.11%, azelastine 0.137%, ipratropium 0.015%-0.09% and low-dose oxymetazoline 0.003125%-0.0125%, compounded at 1 of 2 pharmacies... Analyses using Z-tests demonstrated statistical improvement across reported symptoms, including nasal congestion. These results support that personalized, multi-ingredient intranasal therapy is associated with significant improvement in the majority of patient-reported rhinitis symptoms. Future controlled studies with validated patient outcome measurements (RQLQ or TNSS) are warranted."

Clinical • CNS Disorders • Inflammation • Pruritus • Sleep Disorder

Novel Approaches to the Management of Non-allergic Rhinitis (NAR) (ACAAI 2026) - "Objective 2: Pharmacologic management of NAR including intranasal corticosteroids, intranasal antihistamines, intranasal ipratropium, and combination strategies; trigger avoidance and behavioral strategies; and evidence for and against other therapies (capsaicin, decongestants, systemic antihistamines). Objective 3: Speaker will cover when to refer to ENT (failure of medical therapy, anatomical contributors). Procedural options including turbinate reduction, radiofrequency ablation, vidian neurectomy, and septoplasty will be discussed, as well as how multidisciplinary care (allergy + ENT) can improve outcomes."

Allergic Rhinitis • Immunology • Inflammation

General Emergency Department Management of Pediatric Asthma Exacerbations: The Impact of Pediatric Readiness on Guideline-Concordant Care. (PubMed, J Asthma) - "The primary outcome was receipt of asthma care in accordance with international guidelines defined as receipt of systemic corticosteroids and inhaled albuterol and ipratropium bromide...Patients receiving guideline-concordant care had higher rates of ICU admission and longer hospital lengths of stay. In this cohort, 1 in 4 children did not receive guideline-concordant asthma exacerbation care at general EDs. Pediatric readiness was not associated with receipt of guideline-concordant care highlighting that preparedness to deliver disease-specific management for common pediatric emergencies, such as asthma, may represent an important yet insufficiently captured component of pediatric readiness."

Journal • Asthma • Critical care • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Rhabdomyolysis in a 10-month-old child: A case report and literature review. (PubMed, Medicine (Baltimore)) - "The recognition of RM in children should be improved. Clinicians should be vigilant when encountering atypical symptoms in conjunction with substantially elevated serum CK. Early and accurate diagnosis, along with active fluid resuscitation, can effectively reduce the incidence of ARF and improve prognosis."

Journal • Review • Acute Kidney Injury • Cough • Infectious Disease • Musculoskeletal Pain • Nephrology • Pain • Pediatrics • Renal Disease • Respiratory Diseases • MB

Safety, Efficacy, and Feasibility of Nebulized Long-Acting Bronchodilators vs Short-Acting Bronchodilators in Hospitalized Patients With Acute Exacerbations of COPD: A Phase IV, Randomized, Parallel-Group Clinical Trial. (PubMed, CHEST Pulm) - "There were no serious adverse events or treatment failures in either group. Our findings indicate that in nonventilated hospitalized patients with exacerbations of COPD, the institution of nebulized formoterol/revefenacin in combination within 24 to 36 hours of hospital admission provided convenient dosing and required fewer drug doses to achieve comparable efficacy and safety with the standard short-acting nebulized albuterol/ipratropium combination."

Journal • P4 data • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: University of Tennessee Graduate School of Medicine | Recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical Studies Using Intranasal Therapies for Parkinson's Disease: A Review. (PubMed, Adv Pharm Bull) - "intranasal glutathione was safe and showed better bioavailability...Intranasal cholecystokinin and ipratropium bromide did not show significant benefits. Intranasal desmopressin is a safe and effective medication for nocturnal polyuria in Parkinson disease...Finally, Rivastigmine nasal spray offered better bioavailability and fewer side effects compared with conventional forms...This review highlights the potential applications, efficacy, and side effects of various intranasal medications for Parkinson's disease and proposes using new interventions for future studies. The general benefits of nasal administration for Parkinson's disease treatment include localized effects, fewer side effects, faster onset of action, improved bioavailability, and enhanced therapeutic effectiveness."

Journal • Review • CNS Disorders • Hypoglycemia • Movement Disorders • Otorhinolaryngology • Parkinson's Disease • Transplantation

Bronchodilator Responsiveness in Preterm-Born Children With Chronic Lung Disease: Importance of Individualized Testing. (PubMed, Pediatr Pulmonol) - "In our cohort, 87% of preterm-born children with CLDI exhibit reversible bronchial obstruction, with a substantial subset responding exclusively to a single bronchodilator. Due to the fact that single-drug testing may underestimate reversibility, individualized bronchodilator testing should be incorporated into care, and its long-term implications merit further study."

Clinical • Journal • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Effect of ipratropium bromide on the interfacial organization of model lung surfactant membranes. (PubMed, Colloids Surf B Biointerfaces) - "GIXD and XRR measurements showed that it does not alter the in-plane or vertical structure of DPPC, but significantly affects DPPG by inducing structural features characteristic of lower-pressure phases and slightly increasing electron density in the headgroup region. Molecular dynamics simulations confirmed preferential localization of ipratropium bromide near DPPG headgroups, driven mainly by electrostatic interactions."

Journal

Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy. (PubMed, Front Pharmacol) - "During hospitalization, inhaled budesonide plus ipratropium bromide (a bronchodilator) was briefly administered...Enzyme replacement therapy (ERT) with agalsidase alfa (0.2 mg/kg every 2 weeks) was initiated as long-term disease-modifying treatment...Respiratory physicians should strictly adhere to COPD diagnostic criteria. Once Fabry disease is diagnosed, ERT should be prioritized as the disease-modifying therapy, and bronchodilators, if used at all, should be reserved for symptomatic patients as an adjunct, not a substitute."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Fabry Disease • Genetic Disorders • Immunology • Lysosomal Storage Diseases • Metabolic Disorders • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases

Should Nebulized Ipratropium Bromide Be Added to Standard Treatments of Pediatric Asthma Exacerbations in the Emergency Department? (PubMed, Ann Emerg Med) - No abstract available

Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Ipratropium bromide nebulization plus SOM: Protective effects in severe pneumonia with respiratory failure. (PubMed, Pak J Pharm Sci) - "In patients with SP+RF, SOM plus ipratropium bromide nebulization significantly improves oxygenation status, respiratory mechanics, and inflammatory stress responses, shortens the duration of mechanical ventilation and the length of hospital stay, and reduces the risk of MODS."

Journal • Retrospective data • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases

Effect of Ipratropium Bromide on EILO (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Cook Children's Health Care System | Trial completion date: Mar 2029 ➔ Dec 2029 | Trial primary completion date: Mar 2029 ➔ Dec 2029

Trial completion date • Trial primary completion date • Pediatrics • Pulmonary Disease

Effect of inhaled anticholinergics on bronchial secretions: a systematic review. (PubMed, Front Physiol) - "Under stable clinical conditions, inhaled ipratropium and tiotropium showed no significant changes in sputum volume, viscosity, or mucociliary clearance compared with placebo...Overall, the findings support a favorable safety profile of these agents regarding airway secretion management. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024575999."

Journal • Review • Cough • Respiratory Diseases • MUC5AC • MUC5B

Association Between the Child Opportunity Index 3.0 and Critical Asthma in Children (PAS 2026) - "Primary outcome was incidence of critical asthma exacerbation, defined by using adjunctive medications (ipratropium, terbutaline, aminophylline, magnesium, epinephrine, ketamine). We identified 1,153 hospitalizations from 902 unique patients (Table 1). COI 3.0 quintile was very low in 553 (48%), low in 251 (21.8%), moderate in 181 (15.7%), high in 89 (7.7%), and very high in 79 (6.9%) hospitalizations. We did not find an association between critical asthma and COI 3.0 (aRR by quintile: low 1.10 (0.96, 1.27), moderate 1.00 (0.82, 1.21), high 0.96 (0.74, 1.25), very high 1.05 (0.79, 1.39))."

Clinical • Asthma • Immunology • Respiratory Diseases

Optimizing the Management of Pediatric Bronchiolitis: A Multi-cycle Clinical Audit at a Regional Hospital in Oman. (PubMed, Cureus) - "Over the four cycles, chest radiography (CXR) decreased from 82% (18/22) to 40.9% (27/66) (p<0.001), salbutamol use decreased from 91% (20/22) to 22.7% (15/66) (p<0.001), ipratropium bromide use decreased from 59% (13/22) to 9% (6/66) (p<0.001), corticosteroid use decreased from 31% (7/22) to 6.06% (4/66) (p<0.001), and antibiotic prescriptions decreased from 45% (10/22) to 15.1% (10/66) (p<0.001)...Conclusion Sequential audit cycles with targeted educational interventions significantly improved adherence to evidence-based bronchiolitis management. This approach offers a feasible, replicable model for improving pediatric respiratory care in regional hospital settings."

Journal • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases

Intrapulmonary Percussive Ventilation (IPV) and Lung Compliance in Invasively Ventilated Children (SCCM 2026) - "90% were prescribed additional ACTs, most commonly albuterol (88%), 3% saline (65%), and ipratropium (41%), and 53% were co-administered with IPV.There was no significant percent change from baseline Cdyn at 15 minutes (5.5%, p=0.246) or 3 hours (5.8%, p=0.353), nor was there a difference within the PARDS subgroup at 15 minutes (12.9%, p=0.125). This interim analysis does not show a significant improvement in lung compliance following a single IPV treatment in a heterogeneous group of invasively ventilated children, although differences may not have been detected due to small sample size. It is also possible that changes in compliance would be more appreciable with multiple IPV treatments over time."

Clinical • Compliance • Acute Respiratory Distress Syndrome • CNS Disorders • Respiratory Diseases

Current Treatments for Pediatric Critical Asthma: An Interim Analysis From the CATCHUP Study (SCCM 2026) - "During hospital admission, 134 (33.7%) received ipratropium, 136 (34.2%) received intermittent IV magnesium, 52 (13.1%) received continuous IV magnesium, 45 (11.3%) received IV terbutaline, and 28 (7.0%) received IV aminophylline. Pharmacologic treatments and respiratory support management varies between patients, with ipratropium and magnesium being the most common adjunctive medications and HFNC and NIV both being common support devices used."

Clinical • Acute Lung Injury • Asthma • Immunology • Infectious Disease • Pediatrics • Respiratory Diseases • Septic Shock

The usefulness of the new SOBIstat-F® device in children with severe acute asthma attacks in the emergency department: A randomized clinical trial. (PubMed, J Asthma) - "Protocols for managing severe asthma exacerbations include bronchodilators (short-acting beta-2 agonists and ipratropium bromide) administered by nebulizer or pressurized metered-dose inhaler(pMDI) with a valved holding chamber, corticosteroids IV, and magnesium sulfate IV...Side effects were similar. For the first time, bronchodilator administration using the SOBIstat-F® device was more effective than the conventional method in reducing hospitalizations and improving the clinical condition of children with severe asthma exacerbations."

Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pulmonary infection by Nocardia saintgeorgesii mimicking lung cancer with concurrent pulmonary embolism in an immunocompetent host: a case highlighting the diagnostic role of mNGS. (PubMed, Front Cell Infect Microbiol) - "Empirical antibiotic therapy with piperacillin-tazobactam was initiated initially, supplemented with inhaled ipratropium bromide and expectorants to alleviate symptoms...The treatment regimen was then adjusted to ceftriaxone sodium combined with compound sulfamethoxazole, and the surgical schedule was canceled...Some literature suggests that many PN patients present with concurrent deep vein thrombosis (DVT), suggesting a potential yet underrecognized association between Nocardia infection and thrombotic events. However, this correlation has not been fully reported before."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Lung Cancer • Oncology • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Efficacy of personalized multi-ingredient nasal sprays in patients with rhinitis (AAAAI 2026) - "Methods Based on symptomatology review from an online intake questionnaire, a telehealth provider prescribes a nasal spray with up to 4 of the following ingredients: triamcinolone 0.055%-0.11%, azelastine 0.137%, ipratropium 0.015%-0.09% and microdose oxymetazoline 0.003125%-0.0125% (equivalent to 1/12th to 1/48th standard otc intranasal oxymetazoline)...Post hoc individual chi-squared tests showed statistically significant improvement (p<0.05) for all symptoms except snore. Conclusions Use of Allermi Super Spray resulted in statistically significant improvement of rhinitis symptoms and highlights the efficacy of personalized, targeted multi-ingredient intranasal treatment."

Clinical • CNS Disorders • Glaucoma • Inflammation • Ophthalmology • Otorhinolaryngology • Pruritus • Sleep Disorder • Vascular Neurology

Amphastar Announces FDA Approval for Ipratropium Bromide HFA (ACCESS Newswire) - "Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched....Amphastar plans to launch its Ipratropium Bromide HFA Inhalation Aerosol, previously referred to as AMP-007, early in the second quarter of 2026."

ANDA • Generic launch • Asthma • Chronic Obstructive Pulmonary Disease • Immunology

Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019. (PubMed, Sci Rep) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Effect of Ipratropium Bromide on EILO (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Cook Children's Health Care System

New P2 trial • Pediatrics • Pulmonary Disease